Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Mehta on the Mitigation of Common Immunotherapy-Related Toxicities in Urothelial Cancer

October 30th 2025

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Dr Lynam on the Clinical Implications of Targeted Therapies in Ovarian Cancer

October 29th 2025

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

October 27th 2025

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Dr Lynam on the Efficacy of Trastuzumab Detruxtecan in HER2-Expressing Ovarian Cancer

October 22nd 2025

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.

Dr Jain on Considerations for Sequencing JAK Inhibitors in Myelofibrosis

October 20th 2025

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Lynam on the Importance of FRα Expression Testing in Ovarian Cancer

October 15th 2025

Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.

Dr Jain on Treatment Decision-Making With JAK Inhibitors in Myelofibrosis

October 13th 2025

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Lynam on the Significance of Mirvetuximab Soravtansine in Ovarian Cancer

October 8th 2025

Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia

October 8th 2025

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer

October 7th 2025

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis

October 6th 2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

Sacituzumab Tirumotecan Plus Pembrolizumab Is Set to Be Evaluated in TNBC

October 6th 2025

Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.

Case Study Showcases Potential Role of Targeted Therapy for Secondary T-Cell Lymphoma After CAR T-Cell Therapy

October 4th 2025

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025

October 3rd 2025

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL

October 3rd 2025

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

JNJ-190 Plus Anti–PD-1 Immune Checkpoint Inhibitors Generate Early Antitumor Activity in HNSCC

October 3rd 2025

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

Dr Daver on Persisting Gaps in the Treatment of Relapsed/Refractory Higher-Risk MDS

October 3rd 2025

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Case Study Highlights Tumor Burden Reduction With Paxalisib Combo in Metastatic TNBC

October 3rd 2025

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

Dr Sabari on the FDA Approval of Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC

October 2nd 2025

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Neoadjuvant Daromun Yields Improved Recurrence-Free Survival in Locally Advanced Melanoma

October 2nd 2025

Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.